Authors/Disclosures
|
J. R. Singleton, MD
(University of Utah Department of Neurology)
|
Dr. Singleton has received research support from NIH. |
|
Billie Ann Bixby
|
No disclosure on file |
|
Eva Feldman, MD, PhD, FAAN
(University of Michigan)
|
The institution of Dr. Feldman has received research support from National Institutes of Health. The institution of Dr. Feldman has received research support from Centers for Disease Control and Prevention / Agency for Toxic Substances and Disease Registry. The institution of Dr. Feldman has received research support from Juvenile Diabetes Research Foundation. Dr. Feldman has received intellectual property interests from a discovery or technology relating to health care. Dr. Feldman has a non-compensated relationship as a Editorial Board Member with Journal of the Peripheral Nervous System, Experimental Neurology, Nature Neurology Reviews, Neurobiology of Disease, NeuroRx, Journal of Neurology Neurosurgery and Psychiatry, Scientific Reports, Lancet Neurology, Med (Cell Press Journal) that is relevant to AAN interests or activities. Dr. Feldman has a non-compensated relationship as a Editor-in-Chief with Oxford University Press Contemporary Neurology Series that is relevant to AAN interests or activities. Dr. Feldman has a non-compensated relationship as a Membership Committee Member, Strategic Planning Committee Member, and Chair of Section 07 with National Academy of Medicine that is relevant to AAN interests or activities. Dr. Feldman has a non-compensated relationship as a Associate Editor with Annals of Neurology that is relevant to AAN interests or activities. Dr. Feldman has a non-compensated relationship as a Governance Committee Chair with American Neurological Association that is relevant to AAN interests or activities. Dr. Feldman has a non-compensated relationship as a Membership Committee Member, Strategic Planning Committee Member, Chair of Section 07, Neuroscience Forum, Council Member with National Academy of Medicine that is relevant to AAN interests or activities. Dr. Feldman has a non-compensated relationship as a Committee on Making ALS a Livable Disease Member with National Academy of Sciences, Engineering, and Medicine that is relevant to AAN interests or activities. Dr. Feldman has a non-compensated relationship as a Member, Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) External Oversight Committee with National Institutes of Health that is relevant to AAN interests or activities. |
|
Jonathan M. Goldstein, MD
|
No disclosure on file |
|
James W. Russell, MD, MS, FRPC, FAAN
(Department of Neurology)
|
The institution of Dr. Russell has received research support from NIH. Dr. Russell has received publishing royalties from a publication relating to health care. |
|
|
No disclosure on file |
|
Amanda C. Peltier, MD, MS
(Vanderbilt University)
|
Dr. Peltier has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alnylam. Dr. Peltier has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for astrazeneca. Dr. Peltier has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for CSL Behring. Dr. Peltier has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Csl Behring. Dr. Peltier has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for argenx. Dr. Peltier has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for alnylam. Dr. Peltier has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for astrazeneca. Dr. Peltier has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Goldman Ismail. The institution of Dr. Peltier has received research support from NIH. The institution of Dr. Peltier has received research support from CSL Behring. |
|
|
No disclosure on file |
|
Bradley J. Katz, MD, PhD
|
Bradley J. Katz, MD, PhD has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for axon optics, LLC. Bradley J. Katz, MD, PhD has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for self employed. Bradley J. Katz, MD, PhD has received stock or an ownership interest from Pfizer. Bradley J. Katz, MD, PhD has received intellectual property interests from a discovery or technology relating to health care. |
|
A. Gordon Smith, MD, FAAN
(VCU Health System Department of Neurology)
|
Dr. Smith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Smith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argenx. Dr. Smith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merz. Dr. Smith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sangamo. Dr. Smith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for US Department of Justice. Dr. Smith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Smith has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Eidos. Dr. Smith has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Lexicon. Dr. Smith has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. The institution of Dr. Smith has received research support from NIH (NINDS, NIDDK). Dr. Smith has received publishing royalties from a publication relating to health care. Dr. Smith has received personal compensation in the range of $0-$499 for serving as a Study Section with NIH. |
|
Mark Marriott, MBBS
(Royal Melbourne Hospital)
|
No disclosure on file |